Physician profile
Patrick L Spencer
NPI 1861494304
$13,394.80
in general payments reported to CMS, 2019-2025
38 companies · $2,200 in 2025
The $2,200 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $1,174 · 2021: $1,345 · 2022: $2,104 · 2023: $3,613 · 2024: $1,552 · 2025: $2,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,364.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,383.97 | 2019-2025 | Hydrus Microstent, Clareon, Clareon Panoptix Pro |
| Abbvie INC. | $1,290.08 | 2022-2025 | Xen Glaucoma Treatment System, Durysta |
| Allergan, INC. | $1,051.84 | 2019-2022 | |
| Amgen INC. | $1,012.96 | 2024-2025 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $573.94 | 2021-2025 | Eylea Hd |
| Bausch & Lomb Americas INC. | $552.62 | 2023-2025 | Miebo, Vyzulta, Envista Mx60 Iol |
| Horizon Therapeutics Plc | $475.15 | 2021-2023 | Tepezza |
| Ocular Therapeutix, INC. | $423.88 | 2020-2024 | Dextenza |
| New World Medical,INC. | $388.39 | 2023 | |
| Aerie Pharmaceuticals, INC. | $319.35 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $318.92 | 2019-2021 | |
| Ivantis, INC | $291.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $235.25 | 2022-2023 | Spravato |
| Sight Sciences, INC. | $230.58 | 2021-2022 | |
| Alimera Sciences, INC. | $223.73 | 2019-2024 | Iluvien, Yutiq |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $201.46 | 2023-2025 | Syfovre |
| Johnson & Johnson Surgical Vision, INC. | $193.90 | 2022-2025 | Catalys System, Tecnis Simplicity |
| Astellas Pharma US INC | $182.24 | 2024-2025 | Izervay |
| Abbott Laboratories | $178.42 | 2022-2025 | Proclaim |
| Oyster Point Pharma, INC. | $176.72 | 2023-2025 | Tyrvaya, Ryzumvi |
| Shire North American Group INC | $170.61 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $155.18 | 2025 | Xdemvy |
| Microsurgical Technology, INC. | $152.48 | 2022 | |
| Mallinckrodt Hospital Products INC. | $147.53 | 2024 | Acthar |
| Sandoz INC. | $144.80 | 2024 | Cimerli |
| Ani Pharmaceuticals, INC. | $123.06 | 2024 | Purified Cortrophin Gel |
| Biohaven Pharmaceuticals, INC. | $119.29 | 2021 | |
| Biotissue Holdings INC. | $115.09 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.23 | 2020 | |
| Rxsight INC | $96.80 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Rayner Intraocular Lenses Limited | $88.61 | 2024-2025 | Omidria, Rayone Spheric, Rayone Aspheric |
| Carl Zeiss Meditec, INC. | $50.00 | 2020 | |
| Sun Pharmaceutical Industries INC. | $49.66 | 2021-2025 | Cequa |
| Eyevance Pharmaceuticals LLC | $45.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $37.82 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35.00 | 2019-2020 | |
| Biogen, INC. | $24.10 | 2024 | Byooviz |
| Harrow Eye, LLC | $21.87 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.